Sickle Cell Anemia Testing & Screening

Sickle Cell Anemia Testing & Screening Market Outlook

The global Sickle Cell Anemia Testing and Screening Market is projected to reach USD 1.2 billion by 2035, growing at a compound annual growth rate (CAGR) of around 8.5% during the forecast period from 2025 to 2035. Factors contributing to the growth of this market include the rising prevalence of sickle cell disease (SCD) worldwide, increased awareness about early diagnosis, and advancements in testing technologies. Furthermore, initiatives by various governments and health organizations aimed at screening newborns and providing comprehensive care to affected individuals are expected to propel market growth. This push for improved healthcare infrastructure, particularly in developing regions, will further create opportunities for SCD testing and screening solutions. Continuous investment in research and development for novel testing methods will also play a vital role in enhancing market dynamics.

Growth Factor of the Market

One of the primary growth factors for the Sickle Cell Anemia Testing and Screening Market is the rising incidence of sickle cell disease, which is particularly prevalent in regions such as sub-Saharan Africa, India, and the Middle East. Increased awareness about the importance of early diagnosis has driven demand for effective screening methods. Additionally, initiatives like universal newborn screening programs have contributed significantly to market expansion, as they ensure timely intervention and management of the disease. Moreover, the advancements in diagnostic technologies, such as high-performance liquid chromatography and molecular testing, have facilitated accurate and rapid diagnosis, further boosting the market. The growing interest in personalized medicine and targeted therapies has also catalyzed the development of innovative testing solutions, aligning with the broader trends in healthcare. Lastly, collaborations between government and private sectors to improve awareness and access to testing services are expected to provide a significant impetus to market growth.

Key Highlights of the Market

• The global market is expected to reach USD 1.2 billion by 2035, with a CAGR of 8.5% from 2025 to 2035.
• Increasing prevalence of sickle cell disease drives demand for effective testing and screening methods.
• Technological advancements in diagnostic tools enhance accuracy and reduce turnaround times.
• Government initiatives for newborn screening and awareness campaigns significantly contribute to market growth.
• Emerging markets in Asia Pacific and Africa present new opportunities for market expansion.

By Test Type

Hemoglobin Electrophoresis :

Hemoglobin electrophoresis is a crucial testing method used to identify different types of hemoglobin in a blood sample, which is particularly useful in diagnosing sickle cell anemia. This method separates various hemoglobin variants based on their electrical charge, allowing for the detection of abnormal hemoglobin types, including hemoglobin S that characterizes SCD. The growing demand for accurate and reliable diagnostic tests has led to an increase in the adoption of hemoglobin electrophoresis in clinical laboratories. Its effectiveness in diagnosing hemoglobinopathies and monitoring disease progression contributes to its steady growth in the market. Furthermore, technological advancements in electrophoresis systems are expected to enhance testing efficiency and accessibility, driving further adoption in both developed and developing regions.

Molecular Testing :

Molecular testing encompasses a range of techniques aimed at identifying genetic mutations associated with sickle cell disease, providing precise and early diagnoses. This segment has gained significant traction due to its ability to deliver rapid results and high specificity in detecting sickle cell mutations. The increasing prevalence of genetic disorders and rising awareness about the benefits of early intervention have fueled the demand for molecular testing solutions. Additionally, advancements in technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) have further enhanced the capabilities of molecular testing, allowing for comprehensive genetic analysis. As healthcare providers shift their focus towards personalized medicine, the significance of molecular testing in sickle cell disease management is expected to rise, driving growth in this segment.

Blood Tests :

Blood tests are essential for diagnosing sickle cell anemia and monitoring its complications. These tests typically include complete blood counts, reticulocyte counts, and tests for hemoglobin concentration and hematocrit levels. With the growing awareness of the disease and its impact on patients' health, the demand for blood tests is anticipated to rise significantly. The ease of sample collection and the availability of rapid testing options have made blood tests a preferred choice for both healthcare providers and patients. Advances in laboratory automation and point-of-care testing are expected to improve the efficiency of blood tests, resulting in faster diagnosis and treatment decisions. As a result, the blood tests segment is poised for substantial growth in the coming years, particularly in regions with high disease prevalence.

Prenatal Testing :

Prenatal testing for sickle cell anemia plays a pivotal role in assessing the risk of SCD in unborn children, enabling informed reproductive decisions. Techniques such as chorionic villus sampling (CVS) and amniocentesis are commonly utilized to detect genetic markers associated with sickle cell disease. The increasing awareness and acceptance of prenatal testing among expectant parents have contributed to the growth of this segment. Furthermore, advancements in non-invasive prenatal testing (NIPT) methods are expected to bolster market prospects by providing safer and more accessible options for evaluating genetic risks. As healthcare professionals emphasize the importance of early detection and management of sickle cell disease, the prenatal testing segment is likely to experience significant growth in the upcoming years.

Newborn Screening :

Newborn screening for sickle cell anemia has become a standard practice in many countries, aimed at identifying infants with the condition early in life. This proactive approach allows for timely intervention and management, significantly improving health outcomes for affected children. The growing implementation of universal newborn screening programs has led to increased demand for reliable testing methods in this segment. Advances in technology, such as dried blood spot testing and multiplex assays, have enhanced the efficiency of newborn screening processes, leading to quicker diagnosis and treatment initiation. As healthcare policies increasingly support newborn screening initiatives, this segment is expected to witness robust growth, particularly in regions with high incidence rates of sickle cell disease.

By Screening Type

Universal Screening :

Universal screening refers to the systematic testing of all newborns for sickle cell anemia, regardless of family history or risk factors. This approach has gained traction due to its effectiveness in identifying affected infants early, allowing for prompt medical intervention. The implementation of universal screening programs has led to an increased demand for efficient testing methods and technologies that can facilitate rapid results. As health authorities recognize the importance of preventive care, the universal screening segment is expected to experience significant growth. Furthermore, collaborations between governments and healthcare organizations to promote screening initiatives will further bolster this segment's expansion, ensuring that more infants have access to critical healthcare services.

Targeted Screening :

Targeted screening involves identifying individuals at higher risk of sickle cell disease based on family history, ethnicity, or other factors. This type of screening is crucial, particularly in populations with a known prevalence of sickle cell disease. The targeted screening segment is fueled by the growing recognition of the importance of customized healthcare solutions that address specific population needs. Technological advancements and the integration of genetic counseling services in healthcare systems have enhanced the effectiveness of targeted screening programs. As healthcare professionals aim to increase awareness and accessibility of testing, the targeted screening segment is anticipated to grow steadily, supporting those who are most at risk for developing sickle cell disease.

By User

Hospitals :

Hospitals play a vital role in the Sickle Cell Anemia Testing and Screening Market, serving as primary healthcare facilities where patients receive diagnostic and therapeutic services. With comprehensive healthcare infrastructure, hospitals are equipped to perform a range of tests, including hemoglobin electrophoresis, molecular testing, and blood tests. The increasing patient volume and the emphasis on early diagnosis are driving the demand for testing services within hospital settings. Furthermore, advancements in hospital laboratory technologies and an increase in collaborations with diagnostic companies are expected to enhance the efficiency of sickle cell testing, contributing to the growth of this segment. As hospitals continue to prioritize patient-centered care, their role in the market is likely to expand further in the coming years.

Diagnostic Laboratories :

Diagnostic laboratories are integral to the Sickle Cell Anemia Testing and Screening Market, providing specialized services that focus on accurate and timely diagnosis of sickle cell disease. These laboratories leverage advanced technologies and methodologies to conduct a variety of tests, catering to both healthcare providers and patients. The growing demand for precise diagnostic solutions and the rising incidence of sickle cell disease are major factors contributing to the growth of this segment. Additionally, the increasing collaboration between hospitals and diagnostic laboratories is expected to streamline testing processes and improve turnaround times. As healthcare continues to evolve, the role of diagnostic laboratories in enhancing patient outcomes through effective testing is anticipated to grow significantly.

Blood Banks :

Blood banks play a critical role in managing sickle cell anemia testing and screening, as they are often involved in the collection, testing, and distribution of blood products. In recent years, there has been an increasing focus on ensuring the safety and quality of blood supplies, which necessitates rigorous testing for conditions like sickle cell disease. The growing need for safe blood transfusions and the importance of donor awareness regarding genetic conditions have contributed to the demand for testing services within blood banks. Moreover, advancements in testing technologies and increased investment in blood banking infrastructure are expected to enhance the efficiency of sickle cell testing in these facilities. As the importance of blood banks in managing sickle cell disease continues to rise, they will play a pivotal role in the overall market landscape.

Others :

This category encompasses various other entities involved in the Sickle Cell Anemia Testing and Screening Market, including research institutions, public health organizations, and private clinics. These entities contribute to the market by promoting awareness, conducting research, and providing diagnostic services tailored to specific populations. The growing emphasis on research and innovation in sickle cell disease management has led to increased collaboration between these organizations and healthcare providers. Additionally, advancements in point-of-care testing and telemedicine services have made screening more accessible, particularly in remote areas. As awareness of sickle cell disease continues to grow, the role of these entities in supporting testing and screening initiatives will become increasingly important.

By Technology

High-Performance Liquid Chromatography :

High-performance liquid chromatography (HPLC) is a widely used technology in the diagnosis of sickle cell anemia, particularly for the quantification of hemoglobin variants. This technique offers high sensitivity and specificity, making it an essential tool in clinical laboratories for the accurate diagnosis of sickle cell disease. The increasing adoption of HPLC for routine testing, coupled with advancements in technology, has enhanced its efficiency and reliability. As healthcare providers strive for precision in diagnostics, HPLC is expected to remain a cornerstone technology in the sickle cell testing landscape. Furthermore, the integration of automation in laboratory processes is anticipated to streamline HPLC applications, improving turnaround times significantly.

Polymerase Chain Reaction :

Polymerase chain reaction (PCR) is a revolutionary technology that allows for the amplification of specific DNA sequences, making it highly valuable in the detection of genetic mutations associated with sickle cell disease. PCR technology provides rapid and accurate results, enabling timely diagnosis and intervention. Its ability to identify carrier status and prenatal diagnosis has driven its adoption in clinical settings. As research continues to advance the understanding of sickle cell genetics, the role of PCR in disease management is expected to grow. Furthermore, innovations such as real-time PCR and multiplex PCR techniques are anticipated to enhance diagnostic capabilities, supporting the demand for testing solutions in the sickle cell anemia market.

Enzyme-Linked Immunosorbent Assay :

Enzyme-linked immunosorbent assay (ELISA) is a widely utilized technology for detecting specific proteins in blood samples, providing essential information in the diagnosis of sickle cell disease. ELISA tests are particularly useful for measuring the levels of fetal hemoglobin, which can influence disease severity. The increasing prevalence of sickle cell disease and the need for reliable diagnostic methods have led to the growing adoption of ELISA in clinical laboratories. Additionally, advancements in assay development and automation are improving the efficiency and accuracy of ELISA testing. As healthcare professionals continue to seek effective diagnostic solutions, the significance of ELISA in managing sickle cell anemia is expected to increase, further supporting market growth.

Mass Spectrometry :

Mass spectrometry (MS) is an advanced analytical technique used for the characterization of various biomolecules, including hemoglobin variants in sickle cell disease. This technology offers high precision and sensitivity, enabling the detection of low-abundance proteins and metabolites. The application of mass spectrometry in sickle cell testing is gaining traction due to its ability to provide comprehensive profiles of hemoglobin variants and their interactions. The increasing demand for sophisticated diagnostic tools and the rise of personalized medicine are driving the adoption of mass spectrometry in clinical laboratories. As technological advancements continue to enhance the capabilities of MS, its role in the sickle cell anemia testing landscape is expected to expand significantly.

By Region

The North America region holds a dominant position in the global Sickle Cell Anemia Testing and Screening Market, attributed to the high prevalence of sickle cell disease and substantial healthcare infrastructure. The region's emphasis on advanced medical technologies and extensive research initiatives further propels market growth. The market in North America is expected to exhibit a CAGR of approximately 9.0% during the forecast period, driven by ongoing advancements in testing methodologies and increasing awareness about early diagnosis. Additionally, government support for screening programs and initiatives aimed at improving patient care contribute significantly to the region's market potential.

In Europe, the Sickle Cell Anemia Testing and Screening Market is also witnessing steady growth, primarily due to rising awareness of genetic disorders and increased investment in healthcare initiatives. The implementation of newborn screening programs across various European countries has significantly contributed to the market expansion. The market in Europe is expected to grow at a CAGR of around 7.5%, as healthcare systems focus on enhancing accessibility to diagnostic services. Countries such as the United Kingdom, France, and Germany are leading the market, driven by significant healthcare expenditures and efforts to improve sickle cell management strategies. Overall, the regional dynamics showcase a robust growth trajectory aligned with global trends.

Opportunities

The Sickle Cell Anemia Testing and Screening Market presents numerous opportunities, particularly in emerging economies where the prevalence of sickle cell disease remains high. In regions like sub-Saharan Africa and South Asia, there is a pressing need for improved healthcare infrastructure and access to diagnostic services. Governments and NGOs are increasingly focusing on implementing screening programs and raising awareness about sickle cell disease, creating a conducive environment for market growth. Additionally, advancements in telemedicine and digital health platforms offer innovative solutions for reaching underserved populations, facilitating access to testing and counseling services. The development of cost-effective, user-friendly testing kits tailored for low-resource settings also holds significant potential to expand market reach and improve patient outcomes.

Moreover, with the growing emphasis on personalized medicine and targeted therapies, there is a burgeoning demand for sophisticated testing technologies that can provide comprehensive genetic insights. Research and development initiatives focused on novel diagnostic methods, such as next-generation sequencing and artificial intelligence-based analysis, are expected to create substantial opportunities in the market. Collaborations between healthcare institutions, research organizations, and technology companies can pave the way for innovative solutions that enhance the accuracy and efficiency of sickle cell testing. Overall, the convergence of technological advancements with an increasing focus on preventive healthcare presents a wealth of opportunities for stakeholders in the sickle cell anemia testing and screening market.

Threats

Despite the promising growth prospects of the Sickle Cell Anemia Testing and Screening Market, several threats could hinder its progress. One significant concern is the lack of awareness and understanding of sickle cell disease in various populations, particularly in regions where the disease is less prevalent. This knowledge gap can lead to delayed diagnosis and inadequate access to screening services, ultimately impacting patient outcomes. Additionally, socioeconomic factors, such as poverty and limited healthcare resources, may restrict access to testing and treatment options in low-income areas, further exacerbating health disparities. Furthermore, the stigma associated with genetic disorders may discourage individuals from pursuing testing and counseling services, posing a substantial barrier to early diagnosis and intervention.

Another threat to the market is the potential for regulatory challenges and compliance issues related to testing methodologies and laboratory practices. As the healthcare landscape evolves, ensuring the safety, accuracy, and reliability of diagnostic tests becomes increasingly critical. Compliance with stringent regulatory standards can pose challenges for manufacturers and laboratories, affecting their ability to bring innovative testing solutions to market. Additionally, competition from alternative diagnostic methods and emerging technologies may threaten the market share of established testing solutions. To navigate these challenges, stakeholders must prioritize awareness, education, and collaboration to foster a supportive environment for sickle cell testing and screening.

Competitor Outlook

• Quest Diagnostics
• LabCorp
• Beckman Coulter, Inc.
• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Bio-Rad Laboratories, Inc.
• Medtronic
• Siemens Healthineers
• PerkinElmer, Inc.
• GE Healthcare
• Ortho Clinical Diagnostics
• Abbott Laboratories
• Hematology Diagnostics, Inc.
• Novartis AG
• GSK (GlaxoSmithKline)

The competitive landscape of the Sickle Cell Anemia Testing and Screening Market is characterized by a diverse array of players, including diagnostic service providers, healthcare technology companies, and pharmaceutical firms. These companies are focused on developing and commercializing innovative testing solutions to meet the growing demand for accurate and timely diagnosis of sickle cell disease. The market is marked by strategic collaborations, partnerships, and mergers and acquisitions, which aim to enhance product offerings and expand market reach. Additionally, the emphasis on research and development initiatives has led to the introduction of advanced testing technologies, catering to the evolving needs of healthcare providers and patients alike.

Quest Diagnostics is a leading player in the market, offering a comprehensive portfolio of diagnostic testing services, including specialized tests for sickle cell disease. The company is known for its commitment to innovation, continuously enhancing its testing methodologies and expanding its laboratory capabilities. LabCorp is another major competitor, providing a wide range of laboratory services and leveraging its advanced technology to improve diagnostic accuracy. The company's extensive network of laboratories and partnerships with healthcare providers positions it as a key player in the sickle cell testing landscape. Furthermore, Thermo Fisher Scientific Inc. and Roche Diagnostics are prominent technology providers, focusing on the development of advanced diagnostic tools and platforms that facilitate efficient sickle cell testing and screening.

Companies like Bio-Rad Laboratories and Siemens Healthineers are also making significant strides in the market by offering cutting-edge diagnostic solutions and contributing to advancements in laboratory automation. Their focus on enhancing testing efficiency and accuracy aligns with the growing demand for reliable sickle cell testing methods. Additionally, players such as PerkinElmer and GE Healthcare are investing in research and development to innovate new technologies that address the complexities of sickle cell disease diagnostics. With the increasing emphasis on personalized medicine, pharmaceutical companies such as Novartis AG and GSK are also investing in the development of targeted therapies and companion diagnostics, further shaping the competitive landscape of the sickle cell anemia testing and screening market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 LabCorp
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 GE Healthcare
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Quest Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Diagnostics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Abbott Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Siemens Healthineers
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Beckman Coulter, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GSK (GlaxoSmithKline)
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bio-Rad Laboratories, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Ortho Clinical Diagnostics
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hematology Diagnostics, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Thermo Fisher Scientific Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Sickle Cell Anemia Testing & Screening Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Laboratories
    • 6.1.3 Blood Banks
    • 6.1.4 Others
  • 6.2 Sickle Cell Anemia Testing & Screening Market, By Test Type
    • 6.2.1 Hemoglobin Electrophoresis
    • 6.2.2 Molecular Testing
    • 6.2.3 Blood Tests
    • 6.2.4 Prenatal Testing
    • 6.2.5 Newborn Screening
  • 6.3 Sickle Cell Anemia Testing & Screening Market, By Technology
    • 6.3.1 High-Performance Liquid Chromatography
    • 6.3.2 Polymerase Chain Reaction
    • 6.3.3 Enzyme-Linked Immunosorbent Assay
    • 6.3.4 Mass Spectrometry
    • 6.3.5 Other Technologies
  • 6.4 Sickle Cell Anemia Testing & Screening Market, By Screening Type
    • 6.4.1 Universal Screening
    • 6.4.2 Targeted Screening

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Sickle Cell Anemia Testing & Screening Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Sickle Cell Anemia Testing & Screening market is categorized based on

By Test Type

• Hemoglobin Electrophoresis
• Molecular Testing
• Blood Tests
• Prenatal Testing
• Newborn Screening

By Screening Type

• Universal Screening
• Targeted Screening

By User

• Hospitals
• Diagnostic Laboratories
• Blood Banks
• Others

By Technology

• High-Performance Liquid Chromatography
• Polymerase Chain Reaction
• Enzyme-Linked Immunosorbent Assay
• Mass Spectrometry
• Other Technologies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Quest Diagnostics
• LabCorp
• Beckman Coulter, Inc.
• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Bio-Rad Laboratories, Inc.
• Medtronic
• Siemens Healthineers
• PerkinElmer, Inc.
• GE Healthcare
• Ortho Clinical Diagnostics
• Abbott Laboratories
• Hematology Diagnostics, Inc.
• Novartis AG
• GSK (GlaxoSmithKline)